Stryker reported a 7.7% increase in net sales to $6.5 billion for Q3 2026, driven by organic growth in MedSurg, Neurotechnology, and Orthopaedics. Adjusted earnings per share rose 10.3% to $3.52, reflecting strong operational performance, while reported EPS declined 11.7% to $1.96 due to special charges and impairments. The company repurchased $1 billion in stock and raised its share buyback program by $3 billion. Stryker expects solid Q4 results and maintains positive outlook for 2027 with updated full-year guidance showing organic sales growth of 6.5%-7.0% and adjusted EPS between $14.80 and $14.90.
Stryker's stock price stands at USD 290.00 on Pluang as of Oct 30, 2026 03:12 WIB, down 4.61% in the past day despite the company's strong Q3 sales growth and share buyback announcements. The stock's market cap is $116.61 billion, with all Pluang investors currently buying rather than selling. This shows active interest in Stryker shares even as the price dips from recent highs.
Stryker Corporation, a global leader in medical technologies, reported a 6.1% increase in revenue and EBITDA of $3.45 billion for the first half of 2026. Management forecasts organic revenue growth between 8.3% and 9.3% for the full year, with adjust...
Stryker Corporation has finalized its acquisition of ZuriMED, incorporating the FiberLocker System into its Sports Medicine offerings. This technology enhances rotator cuff repair by improving biomechanical strength, addressing a key clinical need. T...
